Association between periodontal disease due to Campylobacter rectus and cerebral microbleeds in acute stroke patients.

Oral health conditions and cerebral small vessel disease, such as white matter lesions or cerebral microbleeds (CMBs), are associated with the incidence of stroke. The purpose of this study was to examine the associations between oral health conditions (serum IgG titers of periodontal pathogens) with the presence or severity of CMBs in acute stroke patients. From January 2013 to April 2016, acute stroke patients were registered in two hospitals. Serum samples were evaluated for antibody titers against 9 periodontal pathogens using the ELISA method. The cut-off points for reactivity (the positive decision point) to each antigen were defined as more than a mean ELISA unit + 1 standard deviation (after logarithmic transformation) in all subjects. CMBs were evaluated on T2*-weighted MRI. In all, 639 patients were evaluated (ischemic, n = 533 and hemorrhagic, n = 106; 73.1 ± 12.9 years old). Among these patients, 627 were available for CMB evaluation. Among the 9 evaluated periodontal pathogens, only Campylobacter rectus (C. rectus) was associated with the presence of CMBs. the prevalence of positive serum antibody titers against C. rectus was higher among patients with CMBs than among those without CMBs (14.6% vs. 8.7%, P = 0.025). In addition, positive serum antibody titers against C. rectus remained one of the factors associated with the presence of CMBs in multivariate logistic analysis (odds ratio 2.03, 95% confidence interval 1.19-3.47, P = 0.010). A positive serum antibody titer against C. rectus was associated with the presence of CMBs in acute stroke patients.

Déclaration de conflit d'intérêts

Dr. Maruyama reports grants and personal fees from Eisai, grants and personal fees from Pfiser, grants and personal fees from Takeda Pharmaceutical, grants and personal fees from Otsuka Pharmaceutical, grants and personal fees from Nihon Pharmaceutical, grants and personal fees from Teijin Pharma, grants from Shionogi, grants and personal fees from Fuji Film, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Sumitomo Dainippon Pharma, grants and personal fees from Nihon Medi-Physics, grants and personal fees from Bayer, grants and personal fees from MSD, grants and personal fees from Daiichi Sankyo, grants and personal fees from Kyowa Kirin, grants and personal fees from Sanofi, grants and personal fees from Novartis, grants and personal fees from Kowa Pharmaceutical, grants and personal fees from Astellas Pharma, grants and personal fees from Japan Blood Products Organization, grants and personal fees from Mitsubishi Tanabe Pharma, personal fees from Ono pharmaceutical, personal fees from Biogen, personal fees from Bristol-Myers Squibb, grants from Mylan which are unrelated to the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials. All other authors declare that they have no conflicts of interest.